Navigation Links
Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
Date:6/18/2008

New Development Programs to Include Response Prediction to Ovarian Cancer

Treatment, Predicting Risk of Gastric Cancer Recurrence, and

Differentiation of Small Cell From Non-Small Cell Lung Cancer In Addition, the Company has Identified Unique microRNA Biomarkers in the Serum of Colon Cancer Patients, Which may Serve as the Basis for a Future

Test for Colon Cancer New Tests Expected to be Developed and Marketed Through the Company's Clinical Laboratory Improvement Act (CLIA) Certified Laboratory, for Which

a Binding Acquisition Term Sheet has Recently Been Signed

REHOVOT, Israel and JERSEY CITY, New Jersey, June 18 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq: ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today the advancement of three new diagnostic tests into its development pipeline. The Company expects to develop and market the new tests through its own CLIA-certified laboratory, for which the Company recently signed a binding acquisition term sheet.

"We aim to be the leading high-complexity molecular diagnostics company, and we believe we have fine-tuned our product engine. This engine is now capable of producing a stream of products that answer unmet medical needs," said Amir Avniel, CEO and President of Rosetta Genomics. "We believe that by the end of 2009, we will have established a prominent position in the oncology and women's health fields."

Leveraging unique microRNA biomarkers identified using Rosetta Genomics' proprietary microRNA extraction and quantification methods, the new programs will focus on the following indications, which are expected to be clinically available during 2009-201
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Global biostimulants market is expected ... an estimated CAGR of 12.5%. In order to ... with least ecological impacts, farmers are looking to ... crop yield more effectively & efficiently. Biostimulants are ... the return on investments. , Leading companies in ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... November 26, 2014 2014 Deep ... an in-depth research report on the Global Palmitic ... introduces Palmitic Acid, basic information, including definition, classification, ... and news analysis, etc. , For international ... Palmitic Acid market in China and other ...
(Date:11/26/2014)... , Nov. 25, 2014 Bio-Techne Corporation (NASDAQ: ... appointed Robert Gavin to serve in a ... Protein Platforms Division.  Mr. Gavin will be responsible for ... which includes the ProteinSimple business acquired in July 2014 ... San Jose, California -based ProteinSimple develops and ...
Breaking Biology Technology:2019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4SoundConnect Appoints Director of Channel Development & Sales 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... Victhom Human Bionics Inc., "Victhom" (TSX: VHB), today ... at www.victhom.com . The Website features a ... two operating divisions; Neurobionix, which is developing an ... which is developing and manufacturing computerized prostheses for ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that ... present a corporate update at the J.P. Morgan 27th Annual ... Pacific Time. The conference will be held January 12-15, ... Webcast of the presentation may be accessed on the Endo ...
... Inc. (OTC Bulletin Board: NWBO; AIM: NWBS and NWBT) (the ... class action lawsuit, In re Northwest Biotherapeutics, ... agreed to pay in settlement US$1 million, which is to ... be approved by the Court. Additional details about the ...
Cached Biology Technology:Victhom Announces Launch of Enhanced Company Website 2Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference 2Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 2Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action 3
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
(Date:11/2/2014)... , James Dacey explores the ways in which physicists ... innovations from the lab into the commercial market. , ... companies as they move from prototype to product is ... physics-based inventions are usually far from market-ready when initially ... lot more complicated than had been originally thought. , ...
(Date:11/2/2014)... put a flashlight up to our palms to see ... St. Louis engineers are using a similar idea to ... of cancerous tissues and to develop potential treatments. ... Professor of Biomedical Engineering at the School of Engineering ... that allows researchers to better focus light in tissue, ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
... Children,s Research Institute and their collaborators have discovered a ... malformation syndrome that can make it impossible for the ... In a study led by Michael L. Cunningham, MD, ... Center, a research team pinpointed two genes known as ...
... the conditions that zebrafish are kept in could have ... the reliability of results, according to scientists from Queen ... mice, are often used by neuroscientists to explore mechanisms ... to treat behavioural disease such as addiction, attention deficit ...
... Health is seeking to refine and improve lung-cancer screening by ... earlier and more effectively. The trial combines a CT chest ... and seeks to build on recent research demonstrating that CT ... learned that CT screening of high-risk patients can reduce lung-cancer ...
Cached Biology News:Researchers pinpoint genetic pathway of rare facial malformation in children 2Better housing conditions for zebrafish could improve research results 2Better housing conditions for zebrafish could improve research results 3Trial seeks improved lung-cancer screening by combining imaging and biomarkers 2
... powerful solution for all plate washing needs in ... ,The PW 384 provides an excellent solution ... Drug Discovery (Assay development, Screening or Lead Optimization) ... ,The PW 384 has set a standard ...
... Model 1575 immunowash microplate washer, 100-240 V, ... have flat-, U-, or V-bottom wells. This ... needle positions to an accuracy of 0.1 ... overflow washing. It can store up to ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
Biology Products: